Development of rheumatoid arthritis during the course of gefitinib therapy

Authors

  • Gen Ohara University of Tsukuba
  • Hiroaki Satoh University of Tsukuba
  • Mika Kohno University of Tsukuba
  • Daisuke Goto University of Tsukuba
  • Takayuki Sumida University of Tsukuba
  • Nobuyuki Hizawa University of Tsukuba

Downloads

Download data is not yet available.

Author Biographies

Gen Ohara, University of Tsukuba

MD. Member of the medical staff, Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan.

Hiroaki Satoh, University of Tsukuba

MD. Professor, Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki, Japan.

Mika Kohno, University of Tsukuba

MD. Member of the medical staff, Division of Rheumatology Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan.

Daisuke Goto, University of Tsukuba

MD. Member of the medical staff, Division of Rheumatology Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan.

Takayuki Sumida, University of Tsukuba

MD. Professor, Division of Rheumatology Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan.

Nobuyuki Hizawa, University of Tsukuba

MD. Professor, Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan.

References

del Giglio A, Ito C. Gefitinib (Iressa) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center. Sao Paulo Med J. 2004;122(3):128-30.

Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.

Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21(12):2237-46.

Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149-58.

Seiverling EV, Fernanadez EM, Adams D. Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption. J Drugs Dermatol. 2006;5(4):368-9.

Downloads

Published

2009-05-05

How to Cite

1.
Ohara G, Satoh H, Kohno M, Goto D, Sumida T, Hizawa N. Development of rheumatoid arthritis during the course of gefitinib therapy. Sao Paulo Med J [Internet]. 2009 May 5 [cited 2025 Mar. 14];127(3):177-8. Available from: https://periodicosapm.emnuvens.com.br/spmj/article/view/1866

Issue

Vol. 127 No. 3 (2009)

Section

Letter to the Editor

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.